FDA approved fixed-dose combination elbasvir-grazoprevir (Zepatier) for treatment of chronic hepatitis C genotypes 1 or 4
Algolia Search

FDA approved fixed-dose combination elbasvir-grazoprevir (Zepatier) for treatment of chronic hepatitis C genotypes 1 or 4

On January 28, 2016, the fixed-dose combination elbasvir-grazoprevir (Zepatier) was approved by the United States FDA for the treatment of chronic hepatitis C genotypes 1 or 4 infection in adults..

Visit Hepatitis C Online to learn more!